Phase I/II Study With the Combination of Afatinib and Selumetinib in Advanced KRAS Mutant Positive and PIK3CA Wildtype Non-small Cell Lung Cancer

Trial Profile

Phase I/II Study With the Combination of Afatinib and Selumetinib in Advanced KRAS Mutant Positive and PIK3CA Wildtype Non-small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Afatinib (Primary) ; Selumetinib (Primary) ; Capecitabine; Docetaxel; Irinotecan
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms M14AFS
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Jun 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov record.
    • 12 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top